These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7628887)

  • 1. Chemical cardioversion of atrial fibrillation with intravenous dofetilide.
    Sedgwick ML; Lip G; Rae AP; Cobbe SM
    Int J Cardiol; 1995 Apr; 49(2):159-66. PubMed ID: 7628887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.
    Nørgaard BL; Wachtell K; Christensen PD; Madsen B; Johansen JB; Christiansen EH; Graff O; Simonsen EH
    Am Heart J; 1999 Jun; 137(6):1062-9. PubMed ID: 10347332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.
    Singh S; Zoble RG; Yellen L; Brodsky MA; Feld GK; Berk M; Billing CB
    Circulation; 2000 Nov; 102(19):2385-90. PubMed ID: 11067793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study.
    Bianconi L; Castro A; Dinelli M; Alboni P; Pappalardo A; Richiardi E; Santini M
    Eur Heart J; 2000 Aug; 21(15):1265-73. PubMed ID: 10924317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dofetilide for atrial fibrillation.
    Med Lett Drugs Ther; 2000 May; 42(1078):41-2. PubMed ID: 10847114
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter.
    Lindeboom JE; Kingma JH; Crijns HJ; Dunselman PH
    Am J Cardiol; 2000 Apr; 85(8):1031-3. PubMed ID: 10760352
    [No Abstract]   [Full Text] [Related]  

  • 7. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
    McClellan KJ; Markham A
    Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
    Torp-Pedersen C; Møller M; Bloch-Thomsen PE; Køber L; Sandøe E; Egstrup K; Agner E; Carlsen J; Videbaek J; Marchant B; Camm AJ
    N Engl J Med; 1999 Sep; 341(12):857-65. PubMed ID: 10486417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.
    Falk RH; Pollak A; Singh SN; Friedrich T
    J Am Coll Cardiol; 1997 Feb; 29(2):385-90. PubMed ID: 9014993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive atrial inotropic effect of dofetilide after cardioversion of atrial fibrillation or flutter.
    DeCara JM; Pollak A; Dubrey S; Falk RH
    Am J Cardiol; 2000 Sep; 86(6):685-8, A8. PubMed ID: 10980226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of dofetilide in patients with atrial fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study.
    Singh SN
    Card Electrophysiol Rev; 2003 Sep; 7(3):225-8. PubMed ID: 14739718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentially modifiable factors of dofetilide-associated risk of torsades de pointes among hospitalized patients with atrial fibrillation.
    Naksuk N; Sugrue AM; Padmanabhan D; Kella D; DeSimone CV; Kapa S; Asirvatham SJ; Lee HC; Ackerman MJ; Noseworthy PA
    J Interv Card Electrophysiol; 2019 Mar; 54(2):189-196. PubMed ID: 30353374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of toxicity with chemical conversion of atrial fibrillation with dofetilide.
    Brumberg G; Gera N; Pray C; Adelstein E; Barrington W; Bazaz R; Mendenhall GS; Nemec J; Voigt A; Wang NC; Schwartzman D; Saba S; Jain SK
    Am J Cardiol; 2013 Aug; 112(4):505-8. PubMed ID: 23706388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase IV trial evaluating the effectiveness and safety of dofetilide.
    Guanzon AV; Crouch MA
    Ann Pharmacother; 2004; 38(7-8):1142-7. PubMed ID: 15161945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dofetilide-induced long QT and torsades de pointes.
    Aktas MK; Shah AH; Akiyama T
    Ann Noninvasive Electrocardiol; 2007 Jul; 12(3):197-202. PubMed ID: 17617063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group.
    Frost L; Mortensen PE; Tingleff J; Platou ES; Christiansen EH; Christiansen N
    Int J Cardiol; 1997 Jan; 58(2):135-40. PubMed ID: 9049678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dofetilide: a new class III antiarrhythmic agent.
    Roukoz H; Saliba W
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale.
    Nagra BS; Ledley GS; Kantharia BK
    J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):191-5. PubMed ID: 16211208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Considerations for dofetilide use in the elderly.
    Crist LW; Dixon DL
    Consult Pharm; 2014 Apr; 29(4):270-4. PubMed ID: 24704896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome.
    Krahn AD; Klein GJ; Yee R
    Pacing Clin Electrophysiol; 2001 Aug; 24(8 Pt 1):1258-60. PubMed ID: 11523612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.